Outcomes of surgical management for borderline (BR)/locally advanced (LA) pancreatic adenocarcinoma (PAC) after neoadjuvant FOLFIRINOX chemotherapy: Results of an AGEO/French multicenter study.
Daniel Pietrasz , Lysiane Marthey , Mathilde Wagner , Jean-Frédéric Blanc
Journal of Clinical Oncology 32
2
2014
Second-line chemotherapy for advanced biliary tract cancer after failure of gemcitabine plus platinum: Results of an AGEO multicenter retrospective study.
Bertrand Brieau , Laetitia Dahan , Yann De Rycke , Tarek Boussaha
Journal of Clinical Oncology 32 4093 -4093
2
2014
Efficacy and Safety of Two Neoadjuvant Strategies With Bevacizumab in MRI-Defined Locally Advanced T3 Resectable Rectal Cancer: Final Results of a Randomized, Noncomparative Phase 2 INOVA Study.
Christophe Borg , Georges Mantion , Frank Boudghène , Françoise Mornex
Clinical Colorectal Cancer 18 ( 3) 200
4
2019
FOLFOX-aflibercept followed by maintenance therapy with fluoropyrimidine-aflibercept as first-line therapy in patients with metastatic colorectal cancer: A GERCOR single-arm phase II study (VELVET).
Benoist Chibaudel , Thierry Andre , Jean Baptiste Bachet , Dominique Auby
Journal of Clinical Oncology 33 ( 15_suppl) 3567 -3567
2015
FOLFOX alone or combined to rilotumumab or panitumumab as first-line treatment in patients (pts) with advanced gastroesophageal adenocarcinoma (AGEA): An open-label, randomized phase II trial (PRODIGE 17 ACCORD 20 MEGA).
David Malka , Florence Castan , Eric Francois , Olivier Bouche
Journal of Clinical Oncology 33 4013 -4013
12
2015
Nab paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after failure of folfirinox: Results of an AGEO multicenter prospective cohort.
Alix Portal , Simon Pernot , Claire Arbaud , David Tougeron
Journal of Clinical Oncology 33 4123 -4123
9
2015
FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases (RCSM): Results of the FFCD 1102 phase II trial.
Jean Baptiste Bachet , Olivier Lucidarme , Julien Taïeb , Emilie Maillard
Journal of Clinical Oncology 34 3513 -3513
4
2016
Impact of genetic polymorphisms of VEGF pathway on the response to bevacizumab in metastatic colorectal cancer (mCRC): Ancillary study of PRODIGE 9 trial.
Camille Sibertin-Blanc , Aurelie Fabre , Thomas Aparicio , Karine Le Malicot
Journal of Clinical Oncology 34 3534 -3534
2
2016
Assessment of tumor-infiltrating lymphocytes and immune-checkpoints expression in metastatic colorectal cancer patients.
Aurelien Gobert , Rana Mitri , Cristian Mateescu , Roger Mouawad
Journal of Clinical Oncology 34 3608 -3608
2016
Peripheral natural killer cells are a prognostic factor in advanced oesogastric adenocarcinoma and are associated with intestinal types in the randomized trial PRODIGE17-ACCORD20 (UNICANCER GI).
Magali Terme , Simon Pernot , Elie Marcheteau , Florence Castan
Journal of Clinical Oncology 34 4061 -4061
2016
Prognostic value of circulating tumor cells in advanced gastroesophageal adenocarcinomas in the randomized trial PRODIGE 17- MEGA (Unicancer GI-AGEO).
Simon Pernot , Cecile Badoual , Magali Terme , Florence Castan
Journal of Clinical Oncology 34 4030 -4030
2016
Platinum rechallenge in patients with advanced biliary tract carcinoma (ABTC) after failure of gemcitabine (GEM)-platinum combination: A national AGEO retrospective study.
Cindy Neuzillet , Bertrand Brieau , Gregory Manuceau , Benoit Rousseau
Journal of Clinical Oncology 34 4076 -4076
2016
PEPCOL: A randomized noncomparative phase II study of PEP02 (MM-398) or irinotecan in combination with leucovorin and 5-fluorouracil as second-line therapy in patients with unresectable metastatic colorectal cancer--A GERCOR Study.
Benoist Chibaudel , Frederique Maindrault-Goebel , Thierry André , Jean Baptiste Bachet
Journal of Clinical Oncology 33 751 -751
4
2015
Primary tumor resection in colorectal cancer with unresectable synchronous metastases: A review.
Louis de Mestier , Gilles Manceau , Cindy Neuzillet , Jean Baptiste Bachet
World Journal of Gastrointestinal Oncology 6 ( 6) 156 -169
26
2014
Is EUS-guided drainage a suitable alternative technique in case of proximal biliary obstruction?
Frédérick Moryoussef , Adrien Sportes , Sarah Leblanc , Jean Baptiste Bachet
Therapeutic Advances in Gastroenterology 10 ( 7) 537 -544
10
2017
How Does Chemoradiotherapy Following Induction FOLFIRINOX Improve the Results in Resected Borderline or Locally Advanced Pancreatic Adenocarcinoma? An AGEO-FRENCH Multicentric Cohort.
Daniel Pietrasz , Olivier Turrini , Véronique Vendrely , Jean-Marc Simon
Annals of Surgical Oncology 26 ( 1) 109 -117
25
2019
Pathologic Major Response After FOLFIRINOX is Prognostic for Patients Secondary Resected for Borderline or Locally Advanced Pancreatic Adenocarcinoma: An AGEO-FRENCH, Prospective, Multicentric Cohort
Daniel Pietrasz , Lysiane Marthey , Mathilde Wagner , Jean-Frédéric Blanc
Annals of Surgical Oncology 22 ( 3) 1196 -1205
48
2015
Five-year outcomes of FOLFIRINOX vs gemcitabine as adjuvant therapy for pancreatic cancer: a randomized clinical trial
Thierry Conroy , Florence Castan , Anthony Lopez , Anthony Turpin
JAMA oncology 8 ( 11) 1571 -1578
121
2022
Time to recurrence and its relation to survival after recurrence in patients resected for stage III colon cancer
Cosimo Rasola , Pierre Laurent-Puig , Thierry André , Antoine Falcoz
European Journal of Cancer 194 113321 -113321
1
2023
hENT1 testing in pancreatic ductal adenocarcinoma: Are we ready yet? A comparative analysis of the murine and the rabbit antibodies
Jerome Cros , Raphaël Maréchal , Jean Baptiste Bachet , Pierre Laurent-Puig
Cancer Research 75 ( 15_Supplement) 580 -580
2015